MedTrace Logo

GLP-1 Infusion and Long-Time Fasting

NCT00285896 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2008-07-11

No results posted yet for this study

Summary

GLP-1 is an incretin hormone that simulates insulin secretion and inhibits glucagon secretion in a glucose dependent way. Below normal plasma glucose levels the effects of GLP-1 stop and the risk of hypoglycemia is small. However no results exits on the effects pharmacologically relevant doses of GLP-1 during long-time fasting. There seems to be a risk of hypoglycemia in healthy people after a fasting period when a glucose load is administered. The risk of hypoglycemia when GLP-1 is administered will be evaluated during these two conditions.

Conditions

Interventions

DRUG

Glucagon-like-peptide-1 (7-36) amide

Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours

DRUG

Placebo

continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Ole E. Schmitz, Professor · Department of pharmacology, Aarhus university

  • Birgitte Brock, MD · Department of Pharmacology ,University of Aarhus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2006-10-31
Completion
2007-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00285896 on ClinicalTrials.gov